IDEXX reported third-quarter revenue of $1,214,237 thousand, up 9.9%, and operating income of $402,348 thousand, up 13.4%; nine-month revenue rose 11.2% to $3,571,642 thousand.
IDEX reported third-quarter organic revenue growth of 10%, EPS of $4.01, and raised full-year revenue outlook to $4,741,000,000 to $4,767,000,000 and EPS outlook to $14.96 to $15.16 per share, citing strong execution and CoVet.
IDEXX Laboratories reported third-quarter revenue of $1,214 million, up 10%, and diluted EPS of $4.01, up 18%, as it raised 2026 revenue guidance to $4,741 million - $4,767 million and EPS outlook to $14.96 - $15.16.
Financial resultsRead from the first part of this long document4 source passages
The Company reports revenues of $1,214 million for the third quarter of 2026, an increase of 10% as reported and organic, driven by Companion Animal Group ("CAG") growth of 10% as reported and organic.Third quarter earnings per diluted share (“EPS”) were $4.01, an increase of 18% as reported and 22% on a comparable basis.The Company is updating its full year revenue growth guidance range to $4,741 million - $4,767 million, or reported growth of 10.1% - 10.8%, an increase of $32 million at midpoint, including $5 million related to the recent CoVet acquisition.The Company updated its EPS outlook range to $14.96 - $15.16, a $0.25 increase compared to prior guidance midpoint, reflecting 15% reported and 16% comparable growth.Open the document at this passage
TL;DR.IDEXX reported Q2 2026 revenue up 10% reported/9% organic and raised full-year revenue and EPS guidance while advancing incremental growth investments, though U.S. same-store clinical visits declined 1.3% in the quarter with continued pressure on wellness visits.
Bullish
+Raised full-year 2026 revenue outlook to $4,700M-$4,745M and EPS to $14.69-$14.94, with organic revenue growth outlook raised ~40 bps at midpoint to 8.5%-9.7%
+Q2 organic revenue grew 9% with CAG Diagnostics recurring revenue up 10.3% organically, including nearly 12% international growth
+Q2 comparable operating margin expanded 110 basis points and EPS grew 15% on a comparable basis to $4.27
+Raised full-year free cash flow conversion outlook to 90%-100% of net income
+IDEX InView DX installed base surpasses 9,000 instruments with over 1,600 placements in Q2, on pace for 5,500 full-year placement goal
+Strong growth in Water (13% organic) and LPD (9% organic) plus record sixth straight quarter of DR50+ digital radiography placements
Bearish
−U.S. same-store clinical visits declined 1.3% in Q2, with continued pressure on wellness visits (down ~3.4% per Reference Lab commentary)
−Updated FX assumptions created a $15 million headwind to 2026 reported revenue outlook and a $0.05 EPS headwind
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
1,158 of 1,313 funds reported for Sep 30 · net -1.3M sh shares · +77 new
Insider flowDistributing
Net -$28.6M over 90 days · 100% sells
Short interestRising
2.99% of shares out · ▲ +22.0% MoM · 4.5 days cover
Volume signalNormal
Volume near normal
Institution breadthSteady
1,313 holders — mid 3-yr range
Squeeze score68
elevated · 0–100
Fundamentals
Strong
Revenue growth+10%
Y/Y
Gross margin62%
expanding
EPS growth+23%
Y/Y
Free cash flow$1.1B
ValuationP/E 47.5
rich
Balance sheet$269.8M
net debt
Quant / Vol
risk profile
Moderate
Volatility37%
annualized · 1-yr
Max drawdown−34%
past year
ATR3.5%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
what management promised — and delivered
Beat or met 6 of last 7
Latest guidance
· from the 8-K filed Nov 2, 2026
Operating Margin
· 2026
Lowered
32.1% – 32.3%
Aug 4, 202632.3% – 32.5%→changed toNov 2, 202632.1% – 32.3%
Organic growth
· 2026Non-GAAP
Raised
10.3% – 11%
May 5, 20267.7% – 9.7%→changed toNov 2, 202610.3% – 11%
= Segment and Other Income from Operations - Water 30.27M
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
IDEXX Laboratories reported third-quarter revenue of $1,214 million, up 10%, and diluted EPS of $4.01, up 18%, as it raised 2026 revenue guidance to $4,741 million - $4,767 million and EPS outlook to $14.96 - $15.16.
Dividends per share over the trailing 365 days by ex-date · buyback figures as last
reported in SEC filings ("spent" derived as authorized − remaining; when several
programs run concurrently, authorized is their combined total per the newest filing) ·
components shown separately — trailing-year buyback spend isn't tracked, so no
combined shareholder yield is derived.
